Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 8/20 | 0.64 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.49 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.49 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.49 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 11/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 11/20 | 0.47 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1564462 | 0.91 | MTOR (0.74) | MTORPIK3CAGRIN1GRIN2B | |
| SCHEMBL1564806 | 0.91 | MTOR (0.53) | MTORPIK3CARICTORRPTORMAPKAP1 | |
| SCHEMBL1564318 | 0.84 | MTOR (0.65) | MTORPIK3CAGRIN1GRIN2BMAP3K11 | |
| SCHEMBL1565630 | 0.82 | MTOR (0.56) | MTORPIK3CAMAP3K11 | |
| SCHEMBL1565631 | 0.81 | MTOR (0.73) | MTORPIK3CAGRIN1GRIN2B | |
| SCHEMBL1564515 | 0.81 | MTOR (0.62) | MTORPIK3CAGRIN1GRIN2B | |
| SCHEMBL1565579 | 0.80 | MTOR (0.48) | MTORGRIN1GRIN2BMAP3K11 | |
| SCHEMBL1564630 | 0.79 | GRIN1 (0.53) | MTORGRIN1GRIN2BMAP3K11 | |
| SCHEMBL1564633 | 0.79 | GRIN1 (0.53) | MTORGRIN1GRIN2BMAP3K11 | |
| SCHEMBL1565383 | 0.79 | MTOR (0.65) | MTORRICTORRPTORMAPKAP1MLST8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785438-B2 | Imidazopyridin-2-one derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-8785438-B2 | Imidazopyridin-2-one derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| EP-2308877-B1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-20130338156-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-12-19 | — | — | US | disclosed |
| US-8436012-B2 | Imidazopyridin-2-one derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-8436012-B2 | Imidazopyridin-2-one derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| EP-2308877-A1 | IMIDAZOPYRIDIN-2-ON DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-20110082138-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-07 | — | — | US | disclosed |
| US-20110082138-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082138-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MTOR, MAPKAP1, RICTOR | MTOR 1/4885PIK3CA 127/4885RICTOR 3/4885 |
| US-20130338156-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MTOR, MAPKAP1, RICTOR | MTOR 1/4885PIK3CA 127/4885RICTOR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.